Almost a year to the day after Roche pulled out a partnership on its underperforming cancer therapy Gavreto, Blueprint Medicines has sold US commercial rights to the drug to Rigel Pharma in a deal ...

Singapore-based Rigel Capital is set to announce the final close of its first early-stage fund, Rigel Star, at slightly over $40 million soon, pushing the total capital the firm has raised across its ...